Ionis Pharmaceuticals Stock Falls Over 40% This Year Despite Analysts' Bullish Outlook
Shares of Ionis Pharmaceuticals (IONS) have declined more than 40% this year, trading near half their 52-week high. The stock's drop is attributed to late-stage clinical trial failures and financial losses in the second quarter. Two key programs—pelacarsen and eplontersen—failed to meet primary endpoints in phase 3 trials, raising concerns about future revenue potential. Despite these setbacks, analysts maintain a strong bullish stance on Ionis, with an average price target of $83.82 per share. The company remains a leader in antisense oligonucleotide (ASO) technology and has six approved therapies for rare diseases such as ALS and spinal muscular atrophy. It also has eight candidates in phase 2 or 3 trials. Ionis is transitioning from relying on partnership milestones to commercializing its own products, with Zanvastro being the first independently launched therapy. The drug was recently FDA-approved and could generate over $100 million annually despite treating a very rare condition.
Tickers: $IONS
Topics: Biotech Clinical Trials Investment Outlook Pharmaceuticals R&D Expenses